Bradley Merrill Thompson Quoted in “Citizens Petition Challenges FDA’s Off-Label Rule”

Policy and Medicine

Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Policy and Medicine, in “Citizens Petition Challenges FDA’s Off-Label Rule,” by Thomas Sullivan.

Following is an excerpt:

The FDA has 180 days to respond to a citizen petition, but the agency can respond by saying it is still considering the issue, Bradley Merrill Thompson, a Washington-based attorney with Epstein Becker & Green PC, told Bloomberg BNA. Therefore, the deadline is not really that effective.